1-5 of 5
Zhengxing Qu
Close
Sort by
Journal Articles

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action

Zhengxing Qu, David M. Goldenberg, Thomas M. Cardillo, Victoria Shi, Hans J. Hansen, Chien-Hsing Chang
Journal: Blood
Blood (2008) 111 (4): 2211–2219.
https://doi.org/10.1182/blood-2007-08-110072
Published: 2008
Includes: Supplemental data
Journal Articles

Recombinant Bispecific Monoclonal Antibody (bsMAb) Against CD20 and CD22 Active In Vitro and In Vivo Against B-Cell Lymphomas.

Zhengxing Qu, PhD, Thomas M. Cardillo, PhD, Victoria Shi, MSc, Diana L. Delaney, MSc, Hans J. Hansen, PhD, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD,MD
Journal: Blood
Blood (2006) 108 (11): 2521.
https://doi.org/10.1182/blood.V108.11.2521.2521
Published: 2006
Journal Articles

Multivalent Anti-CD20/Anti-CD22 Bispecific Antibody Fusion Proteins Made by the DNL Method Show Potent Lymphoma Cytotoxicity.

Edmund A. Rossi, PhD, Michele J. Losman, Ph.D., Diane L. Nordstrom, M.S., Thomas Cardillo, Ph.D., Meiyu Loo, M.S., John Kopinski, B.S., Zhengxing Qu, Ph.D., David M. Goldenberg, Sc.D., M.D., Chien-Hsing Chang, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2495.
https://doi.org/10.1182/blood.V108.11.2495.2495
Published: 2006
Journal Articles

Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab

Rhona Stein, Zhengxing Qu, Susan Chen, David Solis, Hans J. Hansen, David M. Goldenberg
Journal: Blood
Blood (2006) 108 (8): 2736–2744.
https://doi.org/10.1182/blood-2006-04-017921
Published: 2006
Journal Articles

Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies

Rhona Stein, Zhengxing Qu, Thomas M. Cardillo, Susan Chen, Adriane Rosario, Ivan D. Horak, Hans J. Hansen, David M. Goldenberg
Journal: Blood
Blood (2004) 104 (12): 3705–3711.
https://doi.org/10.1182/blood-2004-03-0890
Published: 2004